Serum homocysteine concentrations in children with growth hormone (GH) deficiency before and after 12 months GH replacement.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

This open, prospective study was designed to evaluate the effect of growth hormone deficiency (GHD) and GH replacement therapy on serum homocysteine (Hcy) concentration in children with GHD.

Who Took Part

The abstract describes 11 boys taking part.

By PubMed's age tags, the people studied were young children and children, both men and women.

Seventeen healthy children acted as controls and were matched for age, sex and body mass index (BMI).

At study entry, height, weight, blood pressure, serum Hcy, serum IGF-I, total-low density lipoprotein (LDL)- and high density lipoprotein (HDL) cholesterol, triglycerides, free T4, free T3, vitamin B12, folate, glucose and creatinine were measured in all subjects.

How the Study Was Run

The atherogenic index (AI) was also calculated as the ratio of total cholesterol/HDL cholesterol (T/HDL).

What Was Measured

PubMed files the paper under topics including Body Mass Index, Case-Control Studies, Cholesterol, Growth Disorders, Growth Hormone, Homocysteine and Hormone Replacement Therapy.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 11 boys.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2004 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.